What smart money is saying about Vetoquinol SA
1 fund in our archive has pitched Vetoquinol SA — most recently Ennismore European Smaller Companies Fund in December 2025.
Vetoquinol S.A. is a prominent veterinary pharmaceutical enterprise dedicated to the innovation, development, and global commercialization of both medicinal and non-medicinal solutions for animal health. Its operations extend across Europe, the Americas, and the Asia Pacific regions. The company's diverse product portfolio addresses crucial therapeutic areas, including mobility, pain management, and inflammation; dermatological care and hygiene; anti-parasitic treatments; udder health; infectious disease control; reproductive solutions; behavior modification; internal medicine; and cardiovascular-renal support. These offerings cater to a wide spectrum of animals, encompassing livestock such as cattle, sheep, pigs, and poultry, alongside companion animals like dogs. Founded in 1933, Vetoquinol S.A. is headquartered in Lure, France, and functions as a subsidiary of Soparfin SCA.
Get an email when a fund writes about it
Fund coverage · 1 thesis
- Ennismore European Smaller Companies FundDecember 2025
Vetoquinol is a resilient animal health company with high barriers to entry, improving mix, and structural growth supporting attractive upside.
Read the full thesis
Read every full thesis on Vetoquinol SA
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→